Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.immuni.2021.07.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma.
Blood
September 2025
University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic, Hradec Králové, Czech Republic.
Epcoritamab is a subcutaneous CD3xCD20 bispecific antibody approved as monotherapy for relapsed/refractory (R/R) follicular lymphoma (FL). We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R/R FL in arm 2 of EPCORE® NHL-2 (phase 1b/2; NCT04663347). Patients received epcoritamab (2 step-up doses, then 48-mg full doses) for up to 2 years and R2 for up to 12 cycles (28 days/cycle).
View Article and Find Full Text PDFObinutuzumab-induced severe acute thrombocytopenia: a case report and literature review.
Front Immunol
September 2025
Department of Haematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody that is widely used in B-cell lymphomas including follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Multiple clinical studies have shown that compared with rituximab combined with chemotherapy, obinutuzumab combined with chemotherapy can significantly improve the progression-free survival (PFS) of patients, effectively reduce the risk of disease progression, and improve patient prognosis. The main adverse effects of obinutuzumab include infusion reactions, myelosuppression, infection, cardiotoxicity, tumor lysis syndrome (TLS), etc.
View Article and Find Full Text PDF[Diffuse large B-cell lymphoma masquerading as a pressure ulcer].
Ugeskr Laeger
September 2025
Ortopædkirurgisk Afdeling, Københavns Universitetshospital - Holbæk Sygehus.
An 84-year-old man with a history of amputation and follicular lymphoma developed a non-healing ulcer on his stump, initially diagnosed as a pressure ulcer cause by the clinic and lack of B-symptoms. Despite wound care, the lesion worsened. A biopsy revealed de novo diffuse large B-cell lymphoma (DLBCL), non-germinal center subtype.
View Article and Find Full Text PDFGenetically determined body mass index is associated with diffuse large B-cell lymphoma in polygenic and Mendelian randomization analyses.
Int J Cancer
September 2025
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Obesity has been associated with non-Hodgkin lymphoma (NHL), but the evidence is inconclusive. We examined the association between genetically determined adiposity and four common NHL subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, chronic lymphocytic leukemia, and marginal zone lymphoma, using eight genome-wide association studies of European ancestry (N = 10,629 cases, 9505 controls) and constructing polygenic scores for body mass index (BMI), waist-to-hip ratio (WHR), and waist-to-hip ratio adjusted for BMI (WHRadjBMI). Higher genetically determined BMI was associated with an increased risk of DLBCL [odds ratio (OR) per standard deviation (SD) = 1.
View Article and Find Full Text PDFBehavioral investigation of reactive and neoplastic lymphocytes in human lymph nodes in 4D.
PLoS One
September 2025
Institute for general pharmacology and toxicology, Goethe University, University Hospital, Frankfurt/Main, Hesse, Germany.
This study deals with a 4D investigation of lymphocytes in human tissue under reactive and neoplastic conditions. The immune system's response to pathogens highly depends on cell interaction and movement, which makes it essential to analyze these dynamics. To achieve this, we observed cells and their movement in 4D.
View Article and Find Full Text PDF